Related Experiment Video
Updated: Aug 10, 2026

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2
Lymphokine-activated killer (LAK) cells can be generated in vitro by incubation of normal murine or human lymphoid cells in recombinant interleukin-2 (RIL-2). These LAK cells are capable of mediating the lysis of fresh, noncultured tumor cells in 4-hour chromium release assays. The adoptive transfer of LAK cells plus RIL-2 is capable of mediating the inhibition of established pulmonary micrometastases from syngeneic tumors in mice. High-dose RIL-2 administered alone is also capable of mediating these antitumor effects, probably via the production of LAK cells in vivo. The immunotherapeutic effect of RIL-2 but not of LAK cells plus RIL-2 is abrogated in hosts that have received preirradiation with 500 rads. The administration of high-dose RIL-2 is also capable of reducing the growth of solid subdermal tumors as well. The use of LAK cells in conjunction with RIL-2 may be applicable to the treatment of cancer in humans, and clinical trials to evaluate this approach in humans have begun.
Lymphokine-activated killer (LAK) cells can be generated in vitro by incubation of normal murine or human lymphoid cells in recombinant interleukin-2 (RIL-2). These LAK cells are capable of mediating the lysis of fresh, noncultured tumor cells in 4-hour chromium release assays. The adoptive transfer of LAK cells plus RIL-2 is capable of mediating the inhibition of established pulmonary micrometastases from syngeneic tumors in mice. High-dose RIL-2 administered alone is also capable of mediating these antitumor effects, probably via the production of LAK cells in vivo. The immunotherapeutic effect of RIL-2 but not of LAK cells plus RIL-2 is abrogated in hosts that have received preirradiation with 500 rads. The administration of high-dose RIL-2 is also capable of reducing the growth of solid subdermal tumors as well. The use of LAK cells in conjunction with RIL-2 may be applicable to the treatment of cancer in humans, and clinical trials to evaluate this approach in humans have begun.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

